Jun 10, 2020
Nordic Nanovector ASA: Annual General Meeting Held
May 26, 2020
Nordic Nanovector ASA: Results for the First Quarter 2020
May 20, 2020
Nordic Nanovector ASA: Notice of Annual General Meeting on 10 June 2020
May 20, 2020
Nordic Nanovector ASA Announces Proposed Change of the Nomination Committee
May 14, 2020
Nordic Nanovector's Betalutin® Receives Positive Opinion for Orphan Drug Designation from EMA for Marginal Zone Lymphoma (MZL)
Apr 08, 2020
Nordic Nanovector Announces New Date for Annual General Meeting
Mar 27, 2020
Nordic Nanovector ASA Publishes 2019 Annual Report
Mar 24, 2020
Nordic Nanovector ASA - Allocation of PSUs
Mar 23, 2020
Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer
Mar 10, 2020
Nordic Nanovector ASA - Financial calendar
Feb 27, 2020
Nordic Nanovector ASA - Results for the Fourth Quarter and Full Year 2019
Dec 18, 2019
Nordic Nanovector Awarded NOK 12 Million in Funding From the Norwegian Research Council to Advance Alpha37, a Targeted Alpha Therapy for B-cell Cancers
Dec 12, 2019
Nordic Nanovector Provides Update on LYMRIT 37-05 Phase 1 DLBCL Trial
Dec 11, 2019
Nordic Nanovector ASA: Allocation of PSUs
Dec 04, 2019
Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin®-Based Therapies in NHL
Nov 19, 2019
Nordic Nanovector ASA - Results for the Third Quarter 2019
Nov 15, 2019
Nordic Nanovector to Participate in Four Upcoming Investor Conferences
Oct 24, 2019
Nordic Nanovector ASA - Resolution not to Proceed With a Repair Offering
Oct 23, 2019
Nordic Nanovector ASA - Tranche 1 Share Capital Increase Registered
Oct 21, 2019
Nordic Nanovector ASA - Tranche 2 Share Capital Increase Registered